This is the first article confirming HelioLiver is now in full commercial launch through Quest — moving from announcement to reality. It also reveals Helio's expanded pipeline strategy with two new liver cancer tests in development and hints at additional partnership announcements.
Orange County Business Journal reports that Helio Genomics is now in full launch mode for HelioLiver through Quest Diagnostics, with the test commercially available nationwide through Quest's 7,700 patient service centers. CEO Dr. Bharat Tewarie reveals the company is developing two additional liver cancer tests — one to track treatment response and another to monitor for disease recurrence after liver transplant. Tewarie hints at additional partnership announcements in the coming months, stating 'partnerships help us scale in the most efficient manner.' The article also notes Helio submitted its FDA premarket approval application in 2024.